First Plenary Session CONVERGING OR DIVERGING MODELS OF HTA IN EUROPE. Jean-Luc Harousseau, MD
|
|
- Magdalen Walters
- 5 years ago
- Views:
Transcription
1 First Plenary Session Speaker CONVERGING OR DIVERGING MODELS OF HTA IN EUROPE Jean-Luc Harousseau, MD President and Chairman of the Board Haute Autorité de Santé (HAS) Saint-Denis La Plaine, France HTA in Europe Jean-Luc Harousseau Chairman of the Board Haute Autorité de Santé, France ISPOR Berlin October
2 01 Current situation and perspectives in France The French healthcare system National Health Insurance (NHI) Statutory, coverage > 90% of the population Three major funds: salarees, rural workers, self-employed Universal Medical Coverage (CMU) since 2000: for uninsured patients and supplementary coverage under threshold income Supplementary Health Insurance: 92 percent of the population subscribe to supplementary health insurance Which medical services are covered? Hospital care, ambulatory care, prescription drugs For prescription drugs:coinsurance level depends on the therapeutic value. 100% coverage by NHI in 29 chronic diseases 4 2
3 HTA, Reimbursement and Pricing for a new drug: The actors HAS: HTA guidance CEPS Economic Committee for Healthcare Products Price Ministry of Health, M. of Social Security Decision L I S T I N G NHI Union Copayment Level 5 From HTA to pricing and reimbursement Literature Dossier from Pharmaceutical Company ASSESSMENT HAS internal assessors Review of available data APPRAISAL HAS Transparency Committee HAS Guidance Economic Committee Ministry of Health NHI funds Decision on P&R H T A Request for additional data collection 6 3
4 Initial assessment: From HTA to decision making on price and reimbursement Dimensions Criteria Results Clinical aspects clinical efficacy clinical effectiveness Actual Benefit Insufficient Sufficient No reimbursement relative effectiveness Other aspects disease characteristics target population impact on public health impact on healthcare organisation (qualitative) Clinical added value No added value Added value Reimbursement only if price inferior to comparators Price may be higher than comparators P R I C I N G HTA: HAS Guidance Decision: Ministry Pricing: Economic Committee 7 ACTUAL BENEFIT (SMR): reimbursement and copayment level SMR Level of reimbursement by NHI Important 60% moderate 30% minimal 15% insufficient NO REIMBURSEMENT 4
5 ADDED CLINICAL BENEFIT (ASMR) Major (I) Important (II) Moderate (III) Minimal (IV) No Added benefit (V) USED FOR PRICING Link between guidance and decision HAS Guidance Added clinical benefit (ASMR) Price Target population Price Volume agreements Request for additional study Risk sharing agreements 10 5
6 Rules governing price setting Primary considerations when setting prices: added clinical benefit (ASMR), forecast sales volumes, clawback payments in case of overshooting (236 million paid by companies to NHI for 2009) prices of comparators, Link between ASMR and price drugs that provide no added clinical benefit (ASMR V) as assessed by HAS and no savings on treatment costs cannot be reimbursed International reference pricing system when clinical added benefit is major to moderate (ASMR I to III) Internal reference pricing system (using price of therapeutic comparators) for drugs with no or minor clinical added benefit 11 Rules governing price setting Spending objective: ONDAM Parliament adopts every year a national health spending objective (ONDAM), indicative, not compulsory. CEPS task is to obtain the most advantageous price and financial conditions for the NHI system, whilst taking into consideration both the pharmaceutical market as a whole and the limitations of the ONDAM budget, as well as public health needs and the obligation to treat all the companies equally. 12 6
7 Sales of reimbursable drugs : growth is currently controlled Total sales 2010: Euros 25.5 billion. 1.3% increase / 2009 (3% in average for the previous 5 years) In 2012 might be 1.5% (negative for the first time) Slowing down of growth due to : Drugs with insufficient SMR are no longer reimbursed lapsing of patents growing generic substitution Reduced number of new innovative drugs, impact of price management promotion of rational prescribing ( maîtrise médicalisée ) June Why French policy is going to change? Obviously for financial reasons (as in other European countries) - NHI budget (ONDAM) had to be cut down from 2.8% to 2.5 % in 2012 while GDP growth will be near 0% - In 2010 sales of reimbursable drugs represented 18% of NHI Budget - Very high cost of new therapies ( anticancer agents up to Euros / year) CHOICE will become necessary 7
8 Why French policy is going to change? But also for more specific reasons General suspicion regarding healthcare system - the Benfluorex crisis : unknown number of deaths related to a 30 year-old drug due to drug misuse and late recognition of pharmacovigilance signals - More recently publication of a «best seller» book edited by two well-known professors - out of 4000 drugs sold in France 20% might be dangerous and 50% might be useless HTA in France: Current concerns Frequently addressed questions French P/R decision process is too complex, not transparent, non predictable results 8
9 HTA in France: Current concerns Frequently addressed questions French system is too complex, not transparent, non predictable results Are drugs more expensive in France? PRICES OF NEW DRUGS IN EUROPE (2008 IMS Health) France Germany Italy Spain UK ASMR I/II ASMR III ASMR IV ASMR V
10 Generic drugs Prices are higher in France than in most European countries Average Price per unit - Holland 5 Euros - UK 7 Euros - Germany 12 Euros - France 15 Euros HTA in France: Current concerns Frequently addressed questions French system is too complex, not transparent, non predictable results Are drugs more expensive in France? Too many prescriptions? 10
11 Pharma expenditure per capita (USD) France Germany UK HTA in France: Current concerns Frequently addressed questions French system is too complex, not transparent, non predictable results Are drugs more expensive in France? Too many prescriptions? Too many drugs? 11
12 Towards relative effectiveness assessment Many new drugs do not offer clinical added value - In % sufficient SMR for new drugs - but only 8% ASMR I-IV (HAS annual report) Re-assessment is mostly based on comparisons - 3d generation pills vs 2nd generation Recent law on Drug Safety (Dec 29th 2012) - inclusion of a new drug on the positive list of reimbursed agents is linked to comparative clinical trials versus existing therapeutic strategies HAS Guidance Perspectives Clinical assessment: towards a more simple, robust and transparent criterion Towards Relative Therapeutic Index to replace both SMR and ASMR Relative effectiveness assessment will base advice on eligibility to reimbursement, on reimbursement rate as well as estimate of the added clinical benefit Transparency on the assessment methods (parameters to be taken into account, steps taken to conclude on RTI) 24 12
13 HAS Guidance Medico-economic HTA New Law and Decree to strengthen HAS role in documenting the collective added value of technologies. When? - first inscription or reevaluation Which products? - Requested ASMR I to III and - Significant impact on health care expenses (health care organization, price, professionnal practices) How? - Based on data provided by the company - Expected or observed efficiency (comparison with existing drugs or technologies) 02 HTA cooperation in Europe Frame and objectives 13
14 HTA cooperation in Europe: What is the political context? Recommendations from Highl Level Pharmaceutical Forum (2008) Legislative measure (2011): DIRECTIVE on the application of patients rights in cross-border healthcare Decision to set up of a permanent network in place of the 3-year Joint Actions Current situtation: EUnetHTA Joint Action 2 just launched (Oct Oct 2015) New permanent network will be established by November What can we do together? Can HTA bodies develop collaborative actions: to reduce duplication of work? to limit unjustified differences in HTA reports? to improve the appropriateness of the data produced? 28 14
15 Reduce duplication of work Common set of data to be used for HTA reports Core HTA information for rapid assessment of drugs and devices Health problem and current use of technology Description and technical characteristics of the technology Safety Effectiveness 29 Reduce unjustified differences in HTA report Assessment methods: EUnetHTA Methodological guidelines Already produced : 9 guidelines for the assessment of drugs - Choice of comparator - HRQoL - Clinical endpoints - Safety - Composite endpoints - Internal validity - Surrogate endpoints - Applicablity - Direct and indirect comparisons To be produced: Guidelines for the assessment of medical devices and procedures Public consultation on EUnetHTA website 30 15
16 31 Appropriateness of data (1) Early Dialogue between HTA bodies and companies Scientific advice (SA) in place for a long time at regulatory agencies, some HTA bodies implemented SA activities Some joint/parallel Regulatory + HTA SA Current initiative Multi HTA early dialogue 2 pilots conducted June and July 2012 Part of EUnetHTA work plan ( ) Drugs and non-drug technologies 32 16
17 Appropriateness of data (1) Early Dialogue (Cont.) 2 pilots of «multi HTA» early dialogue done (June and July 2012) With voluntary participation of EUnetHTA partners (Germany, UK, Austria, Belgium, Italy, Netherlands, France) Coordinated by HAS (Mira Pavlovic, Anne Gourvil, François Meyer) With support from European Commission (DG SANCO) Practical aspects: Letter of intent: Eligibility? Briefing book: Summary of available data, description of draft development plan, list of questions Meeting between sponsor and HTA bodies 33 Appropriateness of data (2) Disease specific guidelines Currently: ongoing pilot project on Alzheimer Disease Green Park Collaborative (CMTP HTAi) Starting October 2012: Disease specific guidelines part of the EUnetHTA Joint Action 2 (Work Package7) 34 17
18 Appropriateness of data (3) Additional data collection: EUnetHTA objectives Definition of criteria to select new technologies in need of further evidence (published) database (EVIDENT) to share information & facilitate collaboration on additional evidence generation (launched Nov. 5 th, 2012) For some technologies, cooperation of several HTA bodies to define a common research question and a «common core protocol» EMA EUnetHTA cooperation 35 Areas for cooperation / harmonisation Literature Dossier from Pharmaceutical Company Early Dialogue ASSESSMENT HAS internal assessors Review of available data Core HTA information Methodological Guidelines APPRAISAL HAS Transparency Committee HAS Guidance Decicion makers on reimbursement and Price Decision on P&R Request for additional data collection Additional data collection 36 18
19 Conclusion P&R decision processes and criteria for appraisal are still, and will remain, country specific Voluntary cooperation between HTA bodies received a political support and is more and more a reality Significant actions are possible within this network to reduce unjustified differences between local HTA reports/guidance and to improve the quality of the data produced by technologies sponsors Political and regulatory limits in convergence does not limit Scientific exchanges and cooperation 37 Thank you for your attention 19
Pharmaco-Epidemiological Studies. A French experience
Pharmaco-Epidemiological Studies A French experience CVZ, Diemen, December 1 st, 2006 Hubert MECHIN, MD CEO MAPI-NAXIS Lyon, France Vocabulary Pharmaco epidemiological studies Observational studies Post-authorization
More informationEUnetHTA. European network for Health Technology Assessment. European network for Health Technology Assessment JA
EUnetHTA European network for Health Technology Assessment Outline The Making of EUnetHTA EUnetHTA and the HTA Network EUnetHTA Achievements and Tools General Information about HTA 2 The Making of EUnetHTA
More informationEuropean Pharmaceutical Policy: Access for Patients or Improving Competitiveness
European Pharmaceutical Policy: Access for Patients or Improving Competitiveness The s Vision Dr Stefaan Van der Spiegel Policy Officer, Unit F5 DG Enterprise and Industry Study day OSE / RIZIV-INAMI Brussels,
More informationEUCERD RECOMMENDATION FOR A
EUCERD RECOMMENDATION FOR A CAVOMP INFORMATION FLOW RECOMMENDATION OF THE EUROPEAN UNION COMMITTEE OF EXPERTS ON RARE DISEASES TO THE EUROPEAN COMMISSION AND THE MEMBER STATES ON IMPROVING INFORMED DECISIONS
More informationStakeholder Consultation Strategy
Stakeholder Consultation Strategy Strengthening of the EU cooperation on Health Technology Assessment (HTA) 1. Context The present stakeholder consultation aims to provide broad and high quality information
More informationPharmaceutical pricing, i reimbursement, Europe: an overview (I) Elias Mossialos and Reinhard Busse
Pharmaceutical pricing, i reimbursement, HTA and cost containment measures in Europe: an overview (I) Elias Mossialos and Reinhard Busse Policy issues in pharmaceutical markets Structure of the pharmaceutical
More informationThis template is to be used by companies willing to submit an overview of relevant
Briefing book template for pharmaceuticals to support a multi-hta Early Dialogue (ED) December 13 th, 2013 This template is to be used by companies willing to submit an overview of relevant information
More informationNew approaches to pricing & funding and implications for access: the BeNeLuxA Collaboration
New approaches to pricing & funding and implications for access: the BeNeLuxA Collaboration Diane Kleinermans Advisor to the Belgian Minister of Healthcare and Social Affairs 9th European Conference on
More informationISPOR 18th Annual European Congress Tuesday 10 November,13:45-14:45
ISPOR 18th Annual European Congress Tuesday 10 November,13:45-14:45 Introduction Alastair Kent, OBE, Genetic Alliance UK, London, UK Recent HTA decisions Jacco Keja, PhD, IMS Health, Rotterdam, The Netherlands
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL PUBLIC CONSULTATION
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Healthcare systems Health systems and products PUBLIC CONSULTATION Brussels, 31 July 2012 on the modalities of stakeholder consultation in the
More informationHTAs and EMA working together: 23 parallel scientific advice procedures later - what have we learned?
HTAs and EMA working together: 23 parallel scientific advice procedures later - what have we learned? DIA 26th Annual EuroMeeting, Vienna 2014 Jan Regnstrom, MD, PhD Senior Scientific Officer An agency
More informationEarly Engagement: One Stop Shop
Early Engagement: One Stop Shop Indranil Bagchi, Ph.D. Vice President, Payer Insights & Access April 7, 2014 Insert presentation title, GH&V tagline, you and your groups name and date What is Early Scientific
More informationThe Integration of Market Access and Advocacy: The Changing Landscape OCTOBER 2016
The Integration of Market Access and Advocacy: The Changing Landscape OCTOBER 2016 The Integration of Market Access and Advocacy: The Changing Landscape Introduction Healthcare market access and advocacy
More informationMechanism of coordinated access to Orphan Medicinal Products. MoCA. NIHDI Belgium
Mechanism of coordinated access to Orphan Medicinal Products MoCA dr Ri DeRidder NIHDI Belgium Context The Issue: Delays and disparities in access to OMP s Decisions on Pricing and Reimbursement exclusive
More information1. Council conclusions on strengthening the balance in the pharmaceutical systems in the EU and its Member States
PRESS 17/6/2016 PRESS RELEASE Council of the European Union 1. Council conclusions on strengthening the balance in the pharmaceutical systems in the EU and its Member States "The Council of the European
More informationCouncilofthe EuropeanUnion Brussels,28October 2014 (OR.en)
ConseilUE Councilofthe EuropeanUnion Brussels,28October 2014 (OR.en) PUBLIC 14793/14 LIMITE PHARM81 SAN405 MI817 COMPET590 NOTE From: To: Subject: GeneralSecretariatoftheCouncil Delegations DraftCouncilconclusionsoninnovationforthebenefitofthepatients
More informationEUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY
EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Health systems, medical products and innovation Medicines: policy, authorisation and monitoring STAMP 6/31 Summary record STAMP Commission
More informationAdaption of healthcare systems in their management of innovation /hospital specialty products
Adaption of healthcare systems in their management of innovation /hospital specialty products Lisa Taylor Global Pricing and Market Access Principal, IMS Consulting Group Pressures in healthcare expenditures
More informationThe Future of Market Access A FirstWord ExpertViews Dossier Report
AM PL E PA G ES S A G ES S A FirstWord ExpertViews Dossier Report Published Copyright 2016 Doctor s Guide Publishing Limited All rights reserved. No part of this publication may be reproduced or used in
More informationPublications for payors: what evidence do they really need? Ian Pickles, Strategy Consultant, Complete Clarity
Publications for payors: what evidence do they really need? Ian Pickles, Strategy Consultant, Complete Clarity OBJECTIVES FOR THE SESSION To be able to build payer evidence requirements into publication
More informationThe Context in which we operate
Prof. Sergio Pecorelli Presidente Agenzia Italiana del Farmaco Rettore Università degli Studi di Brescia The Context in which we operate Limited Resources Population Ageing Healthcare rights One single
More informationAFSSAPS : Inclusion of external experts into the review process
AFSSAPS : Inclusion of external experts into the review process Pr Philippe Lechat Director of Evaluation of Drugs and of Biological Products, AFSSAPS CHMP alternate member for France 1 AFSSAPS : Assessment
More information6th EUROPEAN CONFERENCE ON RARE DISEASES & ORPHAN PRODUCTS ECRD 2012 Brussels
www.eurordis.org 6th EUROPEAN CONFERENCE ON RARE DISEASES & ORPHAN PRODUCTS ECRD 2012 Brussels Brussels, 24-25 May 2012 www.eurordis.org THE NEW PARADIGMS OF RARE DISEASES TREATMENT DEVELOPMENT & ACCESS
More informationBi Regional Consultation on Good Governance
Pharmaceutical Services Ministry of Health Malaysia GGM PROGRAMME IN MALAYSIA WHO Collaborating Centre For Regulatory Control of Pharmaceuticals Bi Regional Consultation on Good Governance 9 th November
More informationEUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY
EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Health systems, medical products and innovation Medicines: policy, authorisation and monitoring STAMP 4/24 Record STAMP Commission Expert
More informationOffice for support of INNOVATION and KNOWLEDGE of medicinal products. _ Spanish Agency of Medicines and Medical Devices
Office for support of INNOVATION and KNOWLEDGE of medicinal products _ Spanish Agency of Medicines and Medical Devices The Spanish Agency of Medicines and Medical Devices has launched the Spanish office
More informationStrategic vision of Pharma Market
Strategic vision of Pharma Market Evolution 2012-2016 ACIP Presentation, Paris January 30, 2013 Introduction This presentation draws strategic orientations for pharma companies considering the expected
More informationRWE from pre-clinical to launch. RWE from pre-clinical to launch. Standard of care Unmet needs. Disease burden Budget impact.
Real Real World World Data Data Across Across the the Product Product Lifecycle: Lifecycle: RWE from pre-clinical to launch RWE from pre-clinical to launch Standard of care Unmet needs Disease burden Budget
More informationGlobal Forum on Competition
Unclassified DAF/COMP/GF/WD(2014)51 DAF/COMP/GF/WD(2014)51 Unclassified Organisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development 14-Feb-2014 English
More informationECONOMIC EVALUATION AND HEALTH TECHNOLOGY ASSESSMENT IN EUROPE AND USA A Comparative Analysis
Coordinator: Università Bocconi CERGAS Via Röntgen 1 20136 Milan (Italy) www.medtechta.eu ECONOMIC EVALUATION AND HEALTH TECHNOLOGY ASSESSMENT IN EUROPE AND USA A Comparative Analysis Executive Summary
More informationNew WHO Report: Access to new medicines in Europe: Technical review of policy initiatives and opportunities for collaboration and research
New WHO Report: Access to new medicines in Europe: Technical review of policy initiatives and opportunities for collaboration and research Hanne Bak Pedersen Programme Manager Health Technologies and Pharmaceuticals
More informationProposal for a new Directive on the transparency of measures regulating the prices of medicinal products: the European Commission oversteps its role
AIM Brussels, 5 July 2012 Joint policy briefing Proposal for a new Directive on the transparency of measures regulating the prices of medicinal products: the European Commission oversteps its role With
More informationStakeholder Involvement Policy
Stakeholder Involvement Policy EUnetHTA Joint Action 2010-2012 Reference: EUnetHTA Joint Action 2010-2012, Stakeholder Involvement Policy, October 2010 1 1. Objective of the document This document provides
More informationBiosimilar Medicines: Opportunities for Sustainable Healthcare. Opening Address Greg Perry Director General EGA London 3-4 May 2007
Biosimilar Medicines: Opportunities for Sustainable Healthcare Opening Address Greg Perry Director General EGA London 3-4 May 2007 Building on The Generic Medicines Legacy 1. Generic medicines account
More informationUptake of innovative products across EU countries: How to address existing discrepancies?
Fourth European Healthcare Policy Deciders Forum Encouraging and Rewarding Innovation Medicines Policy Effectiveness and efficiency in resource allocation February 17 th 18 th, London Francis Arickx National
More informationPharmamarketing - strategic challenges
Pharmamarketing - strategic challenges Biomedicine Master Program Lund University Course: Biomedicine the Profession Anna Chérouvrier Hansson, MSc. December 16th, 2014 1. Pharmamarketing - definitions
More informationSchool of Economics and Management LIUC University, Castellanza, Italy
Stefano Capri School of Economics and Management LIUC University, Castellanza, Italy scapri@liuc.it ISPOR Issue Panel, Dublin SESSION IV, Wednesday, 6 November 2013 What should health economists, from
More informationPolicies Approved by the 2018 ASHP House of Delegates
House of Delegates Policies Approved by the 2018 ASHP House of Delegates 1801 Unit Dose Packaging Availability To advocate that pharmaceutical manufacturers provide all medications used in health systems
More informationUpdate on Real World Evidence Data Collection
Update on Real World Evidence Data Collection STAMP, 10 March 2016 Presented by Dr Peter Arlett EMA An agency of the European Union What is Real-world evidence? Big data = umbrella term describing large
More informationInnovations in Drug Pricing and Reimbursement:
ADVISORY REPORT AM PL E PA G ES S A S G ES A FirstWord Dossier Advisory report and Reimbursement Published Copyright 2016 Doctor s Guide Publishing Limited Part of the FirstWord Dossier family of reports
More informationPolicy principles for a competitive healthcare environment
Policy principles for a competitive healthcare environment Pharmaceutical Research and Development Industry Malta Association (PRIMA) PRIMA is an affiliate of the European Federation of Pharmaceutical
More informationNovartis Pharma AG Global Clinical Trials Innovation Summit
Novartis Pharma AG Global Clinical Trials Innovation Summit Cornelis Winnips MD, Global Program Medical Director Berlin, October 20, 2016 Novartis is one of the world s largest pharmaceutical companies...
More informationMEDEV COLLABORATION EU ASSESMENT FOR REIMBURSEMENT
EU-assessment for MEDEV reimbursement COLLABORATION EU ASSESMENT FOR REIMBURSEMENT Ad Schuurman Krakow November 25 2008 Some Figures Turnover in Europe: 150,000,000,000.- Investment pharma industry Marketing
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. Health systems and products Medicinal products authorisations, EMA Head of Unit
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products authorisations, EMA Head of Unit PHARM 606 PHARMACEUTICAL COMMITTEE 28 March 2012 68 th meeting
More informationPharma R&D and Patents support Health Care & Economy
Pharma R&D and Patents support Health Care & Economy Konstantinos Μ. Frouzis President of SFEE, V.P & Gen. Manager of Novartis Hellas April 28 th, 2014 Intellectual Property Patents: The vehicle for innovation
More informationAvailability of human medicinal products in Europe how big is the problem and what can we do?
Availability of human medicinal products in Europe how big is the problem and what can we do? Kristin Raudsepp Director General Estonian State Agency of Medicines The presentation Initiative by the regulators
More informationABPI response to European Commission consultation on advanced therapy medicinal products
ABPI response to European Commission consultation on advanced therapy medicinal products 28 March 2013 ABPI response to European Commission consultation on the regulation of advanced therapy medicinal
More informationMarketing Authorisation Routes in the EU
Marketing Authorisation Routes in the EU The EU medicines regulatory system and the European Medicines Agency: an introduction for international regulators and non-governmental organisations 18 September
More informationWorkshop on Access to and Uptake of Biosimilar Medicinal Products
EUROPEAN COMMISSION Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs Consumer, Environmental and Health Technologies Biotechnology and Food Supply Chain Workshop on Access to
More information1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Emerging Pharmaceutical Market - Indonesia and the Philippines -Introduction 3 Emerging
1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Emerging Pharmaceutical Market - Indonesia and the Philippines -Introduction 3 Emerging Pharmaceutical Market - Indonesia and the Philippines
More informationComparing The Effectiveness Of New Drugs: Should The FDA Be Asking 'Does It Work' Or 'Does It Work Better'? Sean R. Tunis, MD, MSc
Moderator Comparing The Effectiveness Of New Drugs: Should The FDA Be Asking 'Does It Work' Or 'Does It Work Better'? Sean R. Tunis, MD, MSc Center for Medical Technology Policy Baltimore, MD, USA COMPARING
More informationVALUE ADDED MEDICINES. Prof. Mondher Toumi, Professor of Public Health, Aix-Marseille University
VALUE ADDED MEDICINES Prof. Mondher Toumi, Professor of Public Health, Aix-Marseille University What Are Value Added Medicines? Value added medicines are defined as medicines based on known molecules that
More informationDETERMINANTS OF ORPHAN DRUG PRICES IN FRANCE: REGRESSION ANALYSIS
DETERMINANTS OF ORPHAN DRUG PRICES IN FRANCE: REGRESSION ANALYSIS Korchagina D 1, Vataire AL 2, Toumi M 3, Falissard B 4, Aballéa S 2 ISPOR 18th Annual European Congress 1 University of Paris-Sud, Paris,
More informationOutline. What HTA Represents in the Reimbursement Review. Principle and HTA Guideline. A Study of HTA PE Dossiers in Taiwan.
New Trends of Health Technology Assessment Development and Value Evidence Requirement for Access and Reimbursement In Asia --PE Analysis Practice in Taiwan ISPOR FORUM (F3): Monday, May 22, 2017, 6:15-7:15
More informationPosition Paper. Executive Summary
Position Paper Status: Final Date of document: 10.10.2017 Hospital Exemption for Advanced Therapy Medicinal Products (ATMPs): greater transparency needed in order to improve patient safety and access to
More informationEARLY ACCESS TO MEDICINES IN EUROPE: COMPASSIONATE USE TO BECOME A REALITY
EARLY ACCESS TO MEDICINES IN EUROPE: COMPASSIONATE USE TO BECOME A REALITY Commission Expert Group on Safe and Timely Access to Medicines for Patients (STAMP) François Houÿez 27 June 2017, Brussels http://www.eurordis.org/publication/early-access-medicines-europe-compassionate-use-become-reality
More informationBULGARIAN PHARMACEUTICAL POLICY AND LEGISLATION IN THE CONTEXT OF THE EU ACCESSION
BULGARIAN PHARMACEUTICAL POLICY AND LEGISLATION IN THE CONTEXT OF THE EU ACCESSION DR SVETLANA SPASSOVA DIRECTOR NATIONAL HEALTH POLICY MINISTRY OF HEALTH European Health Conference 29th September 2006
More informationOverview of the new pharmacovigilance legislation
Overview of the new pharmacovigilance legislation SME workshop: 19 April 2012 Dr Peter Arlett Head, Pharmacovigilance and Risk Management EMA An agency of the European Union In this talk: New legislation
More informationDEVELOPMENT OF MULTIPLE CRITERIA DECISION ANALYSIS FRAMEWORK FOR OFF-PATENT PHARMACEUTICALS DECISION MAKING IN VIETNAM
DEVELOPMENT OF MULTIPLE CRITERIA DECISION ANALYSIS FRAMEWORK FOR OFF-PATENT PHARMACEUTICALS DECISION MAKING IN VIETNAM Introduction Authors: Pham Le Tuan 1, Pham Huy Tuan Kiet 2, Diana Brixner 3, Van Huy
More informationPharmaceutical Policy and Pricing: Are Other Countries Getting Greater Value Alliance for Health Reform 11/7/11
Pharmaceutical Policy and Pricing: Are Other Countries Getting? November 7, 2011 affected, health plans, employers, hospitals and others 2 [START RECORDING] ED HOWARD: If I can have your attention, I'd
More informationEU health policy. Strategy for the pharmaceutical industry and biosimilars. Salvatore D'Acunto. DG Research. DG Internal Market. DG Health & Consumers
Strategy for the pharmaceutical industry and biosimilars Salvatore D'Acunto European Commission Enterprise and Industry Directorate-General London, 3 April 2014 EU health policy DG Research R&D, innovation
More informationThe Beneluxa Initiative
The Beneluxa Initiative Facing the challenges: Equity, Sustainability and Access Aldo Golja, Beneluxa Coordinator Ministry of Health, The Netherlands 1 Introduction 2 Christ Church Cathedral, Dublin Members
More informationExecutive Summary. Variation in per capita expenditure on pharmaceuticals is relatively low across OECD countries...
ISBN 978-92-64-04414-2 Pharmaceutical Pricing Policies in a Global Market OECD 2008 Executive Summary Variation in per capita expenditure on pharmaceuticals is relatively low across OECD countries... The
More informationJOBS FOR EUROPE: THE EMPLOYMENT POLICY CONFERENCE MAXIME CERUTTI, SOCIAL AFFAIRS DIRECTOR, BUSINESSEUROPE
SPEAKING NOTES *** Check against delivery *** 6 September 2012 JOBS FOR EUROPE: THE EMPLOYMENT POLICY CONFERENCE 7 SEPTEMBER 2012 MAXIME CERUTTI, SOCIAL AFFAIRS DIRECTOR, BUSINESSEUROPE Introductory comments
More informationLicense Agreement of Tildrakizumab for Psoriasis in Europe
License Agreement of Tildrakizumab for Psoriasis in Europe July 28 th 2016 Disclaimer This document has been prepared by Almirall, S.A. (the Company ) exclusively for use during the presentation. This
More informationRegulatory update from Europe:
Regulatory update from Europe: Procedures to promote early access of medicinal products to the market Elmer Schabel MD Regulatory update from Europe - Overview Current tools for early access Conditional
More informationPhRMA Days Press Conference
PhRMA Days Press Conference April 12, 2017 Joaquin Duato Chairman of the Board, PhRMA Roadmap I. Recent Developments in the United States II. Biopharmaceutical Industry s Contribution to Innovation and
More informationReimbursement of high cost drugs the Polish experience
Reimbursement of high cost drugs the Polish experience 1. Poland and Polish health care system 2. AHTAPol tasks and activities Iga Lipska, M.D. Deputy Director Bogusława Osińska, M.D. Chief Specialist,
More informationNews For Immediate Release
News For Immediate Release Contact: Gary Gatyas IMS Institute for Healthcare Informatics (610) 244-2600 ggatyas@us.imshealth.com IMS Study Forecasts Rebound in Global Spending on Medicines, Reaching Nearly
More informationCommission's proposal to review EU pharmaceutical legislation
SPEECH/01/354 Mr Erkki Liikanen Member of the European Commission, responsible for Enterprise and the Information Society Commission's proposal to review EU pharmaceutical legislation Press conference
More informationRegulatory point of view on clinical benefit assessment and parallel EMA/HTA advice
Regulatory point of view on clinical benefit assessment and parallel EMA/HTA advice Ateliers de Giens Meeting - French Society of Pharmacology and Therapeutics - Paris, March 23rd 2016 An agency of the
More informationEUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL
EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL Health systems, medical products and innovation Medicines: policy, authorisation and monitoring PHARM 723 PHARMACEUTICAL COMMITTEE 18 October
More informationInsights into the Evolving Pricing & Market Access Environment
Insights into the Evolving Pricing & Market Access Environment UBC Global Market Access Survey July 2012 JULY 2012 GLOBAL MARKET ACCESS SURVEY UBC s Global Market Access Survey: Setting the Stage For those
More informationEuropean Regulations for Medicines Place and Role of the EDQM and the European Pharmacopoeia
European Regulations for Medicines Place and Role of the EDQM and the European Pharmacopoeia Cathie VIELLE Head of the Ph. Eur. Department, EDQM Structure Council of Europe, European Union and EDQM The
More informationBelgium, a European leader in clinical trials
Belgium, a European leader in clinical trials An attractive country for clinical trials to test innovative medicines In Europe it is nearly impossible to find other countries with as many clinical trials
More informationScientific advice and its impact on marketing authorisation application reviews
Scientific advice and its impact on marketing authorisation application reviews SME info day: Tools to support innovative medicines development and early access Presented by Jan Regnström, MD, PhD Scientific
More informationENCePP Plenary: New Pharmacovigilance legislation
ENCePP Plenary: New Pharmacovigilance legislation 18 November 2010 Peter Arlett Head of Pharmacovigilance and Risk Management EMA An agency of the European Union In this talk 1. New pharmacovigilance legislation:
More informationId. 3. Id. Docket # USTR Edward Gresser Chair of the Trade Policy Staff Committee Office of the United States Trade Representative
Docket # USTR-2018-0034 Edward Gresser Chair of the Trade Policy Staff Committee Office of the United States Trade Representative The Biotechnology Innovation Organization (BIO) appreciates the opportunity
More informationEMA Adaptive licensing: a tool concept for accelerated access to innovative medicines? Rob Hemmings, MHRA
EMA Adaptive licensing: a tool concept for accelerated access to innovative medicines? Rob Hemmings, MHRA Slides largely re-produced from a previous EMA presentations to (DIA, Paris; STAMP, Brussels).
More informationThe Price of Global. Drug Pricing Strategies to Balance. Patient Access and the Funding of
The Price of Global Health Drug Pricing Strategies to Balance Patient Access and the Funding of Innovation Second Edition ED SCHOONVELD GOWER Contents List offigures ListofTables List of Abbreviations
More informationCASE STUDY: USING MARKET FORCE TEMPLATE TO UNDERSTAND PHARMA RETAIL MARKETS IN FRANCE
CASE STUDY: USING MARKET FORCE TEMPLATE TO UNDERSTAND PHARMA RETAIL MARKETS IN FRANCE By April Harding BACKGROUND This case study presents examples of retail pharmacy markets to illustrate how to use the
More informationEU Innovation Network
EMA Roundtable Meeting, London, 27 November, 2015 >>www.pei.de EU Innovation Network Federal Agency for Vaccines and Biomedicines Bettina Ziegele - Start 2001: ITF at EMA 2008-2011: first innovation offices
More informationSummary of the Actions of the ASHP House of Delegates. June 3 and 5, 2018
Summary of the Actions of the ASHP House of Delegates June 3 and 5, 2018 The House of Delegates Ultimate authority over ASHP professional policies One annual session consisting of 4 meetings: 2 meetings
More informationThe Drug Importation Debate: An Economic Perspective
The Drug Importation Debate: An Economic Perspective Patricia M. Danzon PhD The Wharton School University of Pennsylvania http://hc.wharton.upenn.edu/danzon/index.htm Effects of Legalizing Drug Importation
More informationJanuary Summary
The Academy of Medical Sciences and the Royal Academy of Engineering joint response to the Medicine and Healthcare products Regulatory Agency s public consultation on the revision of European legislation
More informationReport from the Paediatric Committee on its first anniversary
European Medicines Agency London, 11 July 2008 Doc. Ref. EMEA/PDCO/347884/2008 Report from the Paediatric Committee on its first anniversary The European Medicines Agency s Paediatric Committee (PDCO)
More informationThe role of patients at the EMA
The role of patients at the EMA Nathalie Bere Patient relations coordinator / European Medicines Agency An agency of the European Union What is the European Medicines Agency (EMA) The EMA is the EU regulatory
More informationPatient Involvement in HTA: An example of How and Why. 26 September 2017
Patient Involvement in HTA: An example of How and Why 26 September 2017 Background A pharma company launching a new drug commissioned an HTA evaluation to an Academic Institution in Italy Patient Experts
More informationClinical Development and enabling Regulatory Steps: How to obtain ODD and Scientific Advice at EMA
Clinical Development and enabling Regulatory Steps: How to obtain ODD and Scientific Advice at EMA TELETHON Convention, Riva del Garda (TN) 15 March 2017 Michela Gabaldo Head Alliance Management & Regulatory
More informationFurthering a Member State driven voluntary cooperation to support access to medicines
Conseil UE Council of the European Union Brussels, 27 January 2017 (OR. en) PUBLIC 5170/17 LIMITE SAN 12 NOTE From: To: Subject: General Secretariat of the Council Delegations Furthering a member state
More informationCanada s Patented Medicine Prices Review Board. Michelle Boudreau, Executive Director Market Access Summit November 15-16, 2011
Canada s Patented Medicine Prices Review Board Michelle Boudreau, Executive Director Market Access Summit November 15-16, 2011 Overview Overview of the PMPRB Price Regulation Regime Observations of the
More informationAccess, Affordability and Innovation Focus on High Cost Medicines: Facts and Potential Options
Access, Affordability and Innovation Focus on High Cost Medicines: Facts and Potential Options Ashoke Bhattacharjya, PhD Robert E Campbell Pharmaceutical Seminar Rutgers Business School Feb 15, 2017 1
More informationISPOR Singapore Issue Panel JOINT HTA: THE NEXT STEP FOR THE ASEAN ECONOMIC COMMUNITY?
ISPOR Singapore Issue Panel JOINT HTA: THE NEXT STEP FOR THE ASEAN ECONOMIC COMMUNITY? Sunday 4 th September 2016, 15:45-16:45 ISPOR Singapore Issue Panel JOINT HTA: THE NEXT STEP FOR THE ASEAN ECONOMIC
More informationRegulatory Requirements
Regulatory Requirements CTTI Quality by Design Workshop 28-29 Jan 2013 Rockville, MD Fergus Sweeney, Head, Compliance and Inspections, European Medicines Agency An agency of the European Union Disclaimer
More informationSupporting Innovation through Scientific Advice
Supporting Innovation through Scientific Advice PEARRL Regulatory Science Symposium, 21 st June 2017, University College Cork HPRA Dr Peter Kiely Disclaimer All views expressed in this presentation are
More information29 August Dear Sir/Madam:
29 August 2016 Directorate General for Health and Food Safety DG SANTE Unit B4 "Medical products Quality, Safety and Innovation" European Commission F101 08/058 B-1049 Brussels RE: Public consultation
More informationRe: Public Consultation Paper on the Regulation of Advanced Therapy Medicinal Products
ISCT HEAD OFFICE Suite 201 375 West 5 th Avenue Vancouver, BC Canada V5Y 1J6 Tel: 604-874-4366 Fax: 604-874-4378 isct@celltherapysociety.org www.celltherapysociety.org March 30, 2013 European Commission,
More informationMaking the case for Personalised Medicine
Making the case for Personalised Medicine The biopharmaceutical industry perspective Barbara Freischem Executive Director European Biopharmaceutical Enterprises Who we are EBE represents the voice of biopharmaceutical
More informationIdentifying Critical Factors Pre-launch
Identifying Critical Factors Pre-launch Incorporate pricing and market access into product planning Eric M. Bachman, Director Boston office One Canal Park Cambridge, MA 02141, USA Tel. +1 617 231 4592
More informationThe Situation of Investigator Initiated Trials in Europe. Dr.N.Gökbuget
The Situation of Investigator Initiated Trials in Europe Dr.N.Gökbuget Investigator Initiated Trials in Europe Difficulties and Possibilities 1. Situation for academic clinical trials after the EU directive
More information